In adults with T2D and ASCVD, tirzepatide was noninferior to dulaglutide for a composite CV outcome at a median 4 y

Key Points

• To compare the cardiovascular outcomes of tirzepatide and dulaglutide in adults with T2D and ASCVD.
• Randomized trial
• Evaluated tirzepatide and dulaglutide in adults with T2D and ASCVD
• Follow-up period of 4 years
• Tirzepatide was noninferior to dulaglutide for composite CV outcomes
• Study had a median follow-up duration of 4 years